메뉴 건너뛰기




Volumn 9, Issue 3, 2016, Pages 419-428

Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer

Author keywords

CTLA 4; endocrine toxicities; immunotherapy; NSCLC; PD 1; PD L1

Indexed keywords

ATEZOLIZUMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DURVALUMAB; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PEMBROLIZUMAB; TICILIMUMAB; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR;

EID: 84959534331     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2016.1133289     Document Type: Review
Times cited : (22)

References (41)
  • 1
    • 80455176700 scopus 로고    scopus 로고
    • A decade of advances in treatment for advanced non-small cell lung cancer
    • Gettinger S, Lynch T. A decade of advances in treatment for advanced non-small cell lung cancer. Clin Chest Med. 2011;32:839-851.
    • (2011) Clin Chest Med. , vol.32 , pp. 839-851
    • Gettinger, S.1    Lynch, T.2
  • 2
    • 0026653868 scopus 로고
    • Interleukin-2 andinterferon-alpha in the treatment of patients withadvanced non-small-cell lung cancer
    • Jansen R, Slingerland R, Goey S, et al. Interleukin-2 andinterferon-alpha in the treatment of patients withadvanced non-small-cell lung cancer. J Immunother. 1992;12:70-73.
    • (1992) J Immunother. , vol.12 , pp. 70-73
    • Jansen, R.1    Slingerland, R.2    Goey, S.3
  • 3
    • 0028926389 scopus 로고
    • Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer
    • Schiller J, Morgan-Ihrig C, Levitt M. Concomitant administration of interleukin-2 plus tumor necrosis factor in advanced non-small cell lung cancer. Am J Clin Oncol. 1995;18:47-51.
    • (1995) Am J Clin Oncol. , vol.18 , pp. 47-51
    • Schiller, J.1    Morgan-Ihrig, C.2    Levitt, M.3
  • 4
    • 84862903106 scopus 로고    scopus 로고
    • Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
    • Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455-2465.
    • (2012) N Engl J Med. , vol.366 , pp. 2455-2465
    • Brahmer, J.R.1    Tykodi, S.S.2    Chow, L.Q.3
  • 5
    • 84969395983 scopus 로고    scopus 로고
    • Atezolizumab monotherapy vs docetaxel in 2L/3L nonsmall cell lung cancer: Primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR)
    • Sep 25-29. Abstract 14LBA
    • Vansteenkiste J, Fehrenbacher L, Spira AI, et al. Atezolizumab monotherapy vs docetaxel in 2L/3L nonsmall cell lung cancer: primary analyses for efficacy, safety and predictive biomarkers from a randomized phase II study (POPLAR). European Cancer Congress 2015; Sep 25-29. Abstract 14LBA.
    • (2015) European Cancer Congress
    • Vansteenkiste, J.1    Fehrenbacher, L.2    Spira, A.I.3
  • 6
    • 84924809260 scopus 로고    scopus 로고
    • Evidence and clinical potential
    • Nivolumab in NSCLC
    • Sundar R, Cho B-C, Brahmer JR, et al. Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015;7(2):85-96.
    • (2015) Ther Adv Med Oncol , vol.7 , Issue.2 , pp. 85-96
    • Sundar, R.1    Cho, B.-C.2    Brahmer, J.R.3
  • 7
    • 84862859820 scopus 로고    scopus 로고
    • Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
    • Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443-2454.
    • (2012) N Engl J Med. , vol.366 , pp. 2443-2454
    • Topalian, S.L.1    Hodi, F.S.2    Brahmer, J.R.3
  • 8
    • 42649125225 scopus 로고    scopus 로고
    • PD-1 and its ligands in tolerance and immunity
    • Keir M, Butte M, Freeman G, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677-704.
    • (2008) Annu Rev Immunol. , vol.26 , pp. 677-704
    • Keir, M.1    Butte, M.2    Freeman, G.3
  • 9
    • 77957664158 scopus 로고    scopus 로고
    • Programmed death-1 upregulation is correlated with dysfunction of tumorinfiltrating CD8+ T lymphocytes in human non-small cell lung cancer
    • Zhang Y, Huang S, Gong D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumorinfiltrating CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol. 2010;7:389-395.
    • (2010) Cell Mol Immunol. , vol.7 , pp. 389-395
    • Zhang, Y.1    Huang, S.2    Gong, D.3
  • 10
    • 80052476869 scopus 로고    scopus 로고
    • High expression of PD-L1 in lung cancermay contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
    • Mu C, Huang J, Chen Y, et al. High expression of PD-L1 in lung cancermay contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. Med Oncol. 2011;28:682-688.
    • (2011) Med Oncol. , vol.28 , pp. 682-688
    • Mu, C.1    Huang, J.2    Chen, Y.3
  • 11
    • 33644659256 scopus 로고    scopus 로고
    • Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
    • Peggs KS, Quezada SA, Korman AJ, et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol. 2006;18:206-213.
    • (2006) Curr Opin Immunol. , vol.18 , pp. 206-213
    • Peggs, K.S.1    Quezada, S.A.2    Korman, A.J.3
  • 12
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer
    • Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123-135.
    • (2015) N Engl J Med. , vol.373 , pp. 123-135
    • Brahmer, J.1    Reckamp, K.L.2    Baas, P.3
  • 13
    • 84948574184 scopus 로고    scopus 로고
    • Common Terminology Criteria for Adverse Events (CTCAE),[cited 2015 Nov 13]
    • Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0 [Internet]. [cited 2015 Nov 13]. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf.
    • Version 4.0 [Internet]
  • 14
    • 84924901863 scopus 로고    scopus 로고
    • Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): A phase 2, single-arm trial
    • Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol. 2015;16:257-265.
    • (2015) Lancet Oncol. , vol.16 , pp. 257-265
    • Rizvi, N.A.1    Mazieres, J.2    Planchard, D.3
  • 15
    • 84936791837 scopus 로고    scopus 로고
    • Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
    • Borghaei H, Paz Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(2):123-135.
    • (2015) N Engl J Med. , vol.373 , Issue.2 , pp. 123-135
    • Borghaei, H.1    Paz Ares, L.2    Horn, L.3
  • 16
    • 84929481480 scopus 로고    scopus 로고
    • Pembrolizumab for the treatment of non-small-cell lung cancer
    • Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018-2028.
    • (2015) N Engl J Med. , vol.372 , pp. 2018-2028
    • Garon, E.B.1    Rizvi, N.A.2    Hui, R.3
  • 17
    • 84944734156 scopus 로고    scopus 로고
    • Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC)
    • Abstract 8032
    • Rizvi NA, Brahmer JR, Ou SI, et al. Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). 2015 ASCO Annual Meeting. Abstract 8032.
    • 2015 ASCO Annual Meeting
    • Rizvi, N.A.1    Brahmer, J.R.2    Ou, S.I.3
  • 18
    • 77954801079 scopus 로고    scopus 로고
    • Improved survival with ipilimumab in patients with metastatic melanoma
    • Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711-723.
    • (2010) N Engl J Med. , vol.363 , pp. 711-723
    • Hodi, F.S.1    O'Day, S.J.2    McDermott, D.F.3
  • 19
    • 84863911486 scopus 로고    scopus 로고
    • Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study
    • Lynch TJ, Bondarenko I, Luft A, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol. 2012;30:2046-2054.
    • (2012) J Clin Oncol. , vol.30 , pp. 2046-2054
    • Lynch, T.J.1    Bondarenko, I.2    Luft, A.3
  • 20
    • 84959564276 scopus 로고    scopus 로고
    • Safety and efficacy of first-line nivolumab (Anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC)
    • Sep 7. Abstract ORAL02.05
    • Rizvi N, Gettinger SN, Goldman J, et al. Safety and efficacy of first-line nivolumab (Anti-programmed death-1 [PD-1]) and ipilimumab in non-small cell lung cancer (NSCLC). 16th World conference on lung cancer. 2015 Sep 7. Abstract ORAL02.05.
    • (2015) 16th World Conference on Lung Cancer
    • Rizvi, N.1    Gettinger, S.N.2    Goldman, J.3
  • 21
    • 84939518267 scopus 로고    scopus 로고
    • Phase I/II study (CheckMate 032) of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC)
    • Abstract 7503
    • Antonia SJ, Bendell J, Taylor M, et al. Phase I/II study (CheckMate 032) of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC). 2015 ASCO Annual Meeting. 2015. Abstract 7503.
    • (2015) 2015 ASCO Annual Meeting
    • Antonia, S.J.1    Bendell, J.2    Taylor, M.3
  • 22
    • 84942138310 scopus 로고    scopus 로고
    • Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced nonsmall cell lung cancer (NSCLC): KEYNOTE-021 cohort D
    • Abstract 8011
    • Patnaik AM, Socinski MA, Gubens MA, et al. Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced nonsmall cell lung cancer (NSCLC): KEYNOTE-021 cohort D. 2015 American society of clinical oncology annual meeting. 2015. Abstract 8011.
    • (2015) 2015 American Society of Clinical Oncology Annual Meeting
    • Patnaik, A.M.1    Socinski, M.A.2    Gubens, M.A.3
  • 23
    • 0027181697 scopus 로고
    • Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies
    • Vialettes B, Guillerand MA, Viens P, et al. Incidence rate and risk factors for thyroid dysfunction during recombinant interleukin-2 therapy in advanced malignancies. Acta Endocrinol (Copenh). 1993;129:31-38.
    • (1993) Acta Endocrinol (Copenh) , vol.129 , pp. 31-38
    • Vialettes, B.1    Guillerand, M.A.2    Viens, P.3
  • 24
    • 78751559991 scopus 로고    scopus 로고
    • Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
    • Min L, Vaidya A, Becker C. Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. Eur J Endocrinol. 2011;164:303-307.
    • (2011) Eur J Endocrinol , vol.164 , pp. 303-307
    • Min, L.1    Vaidya, A.2    Becker, C.3
  • 26
    • 84918583260 scopus 로고    scopus 로고
    • Guidelines for the treatment of hypothyroidism: Prepared by the American thyroid association task force on thyroid hormone replacement
    • Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24:1670-1751.
    • (2014) Thyroid , vol.24 , pp. 1670-1751
    • Jonklaas, J.1    Bianco, A.C.2    Bauer, A.J.3
  • 27
    • 84899873585 scopus 로고    scopus 로고
    • Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: A comprehensive retrospective review from a single institution
    • Ryder M, Callahan M, Postow MA, et al. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocr Relat Cancer. 2014;21:371-381.
    • (2014) Endocr Relat Cancer , vol.21 , pp. 371-381
    • Ryder, M.1    Callahan, M.2    Postow, M.A.3
  • 28
    • 79960559927 scopus 로고    scopus 로고
    • Drug-induced Graves disease from CTLA-4 receptor suppression
    • Borodic G, Hinkle DM, Cia Y. Drug-induced Graves disease from CTLA-4 receptor suppression. Ophthal Plast Reconstr Surg. 2011;27:e87-8.
    • (2011) Ophthal Plast Reconstr Surg. , vol.27 , pp. e87-e88
    • Borodic, G.1    Hinkle, D.M.2    Cia, Y.3
  • 29
    • 84888226962 scopus 로고    scopus 로고
    • Endocrine sideeffects of anti-cancer drugs: MAbs and pituitary dysfunction: Clinical evidence and pathogenic hypotheses
    • Torino F, Barnabei A, Paragliola RM, et al. Endocrine sideeffects of anti-cancer drugs: mAbs and pituitary dysfunction: clinical evidence and pathogenic hypotheses. Eur J Endocrinol. 2013;169:R153-64.
    • (2013) Eur J Endocrinol. , vol.169 , pp. R153-R164
    • Torino, F.1    Barnabei, A.2    Paragliola, R.M.3
  • 31
    • 84864067813 scopus 로고    scopus 로고
    • Hyponatremia associated with ipilimumab-induced hypophysitis
    • Barnard ZR, Walcott BP, Kahle KT, et al. Hyponatremia associated with ipilimumab-induced hypophysitis. Med Oncol. 2012;29:374-377.
    • (2012) Med Oncol. , vol.29 , pp. 374-377
    • Barnard, Z.R.1    Walcott, B.P.2    Kahle, K.T.3
  • 32
    • 77949274549 scopus 로고    scopus 로고
    • Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes
    • Dillard T, Yedinak CG, Alumkal J, et al. Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary. 2010;13:29-38.
    • (2010) Pituitary , vol.13 , pp. 29-38
    • Dillard, T.1    Yedinak, C.G.2    Alumkal, J.3
  • 33
    • 84864052441 scopus 로고    scopus 로고
    • Management of immune-related adverse events and kinetics of response with ipilimumab
    • Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012;30:2691-2697.
    • (2012) J Clin Oncol. , vol.30 , pp. 2691-2697
    • Weber, J.S.1    Kähler, K.C.2    Hauschild, A.3
  • 34
    • 84946221495 scopus 로고    scopus 로고
    • Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-smallcell lung cancer
    • [Epub ahead of print]
    • Chow LQM. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-smallcell lung cancer. Am Soc Clin Oncol Educ Book. 2013. doi:10.1200/EdBook-AM.2013.33.e280. [Epub ahead of print]
    • (2013) Am Soc Clin Oncol Educ Book
    • Chow, L.Q.M.1
  • 35
    • 84938309673 scopus 로고    scopus 로고
    • Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC
    • May
    • Antonia SJ, Goldberg SB, Balmanoukian AS, et al. Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. J Clin Oncol (Meeting Abstracts). 2015 May;33 (15):suppl 3014.
    • (2015) J Clin Oncol (Meeting Abstracts) , vol.33 , Issue.15
    • Antonia, S.J.1    Goldberg, S.B.2    Balmanoukian, A.S.3
  • 36
    • 84944802880 scopus 로고    scopus 로고
    • Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer
    • May
    • Oxnard GR, Ramalingam SS, Ahn M, et al. Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer. J Clin Oncol (Meeting Abstracts). 2015 May;33(15):suppl 2509.
    • (2015) J Clin Oncol (Meeting Abstracts) , vol.33 , Issue.15
    • Oxnard, G.R.1    Ramalingam, S.S.2    Ahn, M.3
  • 37
    • 84944728607 scopus 로고    scopus 로고
    • Safety and tolerability results from a phase i study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PDL1) antibody, combined with gefitinib in patients (pts) with nonsmall-cell lung cancer (NSCLC)
    • May
    • Creelan BC, Chow LQ, Kim D, et al. Safety and tolerability results from a phase I study of MEDI4736, a human IgG1 anti-programmed cell death-ligand-1 (PDL1) antibody, combined with gefitinib in patients (pts) with nonsmall-cell lung cancer (NSCLC). J Clin Oncol (Meeting Abstracts). 2015 May;33(15):suppl 3047.
    • (2015) J Clin Oncol (Meeting Abstracts) , vol.33 , Issue.15
    • Creelan, B.C.1    Chow, L.Q.2    Kim, D.3
  • 38
    • 36748999428 scopus 로고    scopus 로고
    • Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade
    • Downey SG, Klapper JA, Smith FO, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007;13:6681-6688.
    • (2007) Clin Cancer Res. , vol.13 , pp. 6681-6688
    • Downey, S.G.1    Klapper, J.A.2    Smith, F.O.3
  • 40
    • 24944459890 scopus 로고    scopus 로고
    • J Clin Oncol. 2005;23:6043-6053.
    • (2005) J Clin Oncol , vol.23 , pp. 6043-6053


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.